mmol/L (126 mg/dL) or glycated hemoglobin A1c ≥ 6.5%, or having a history of diabetes mellitus, or receiving glucose-lowering drugs. Elevated serum creatinine level was defined as serum creatinine ≥ 1.5 mg/dL. Severe clinical conditions, including cardiac shock and cardiac arrest were defined as those with onset within 24 hours of current admission.
The Global Registry of Acute Coronary Events (GRACE) score was calculated based on the collected data. Other comorbidities were collected from medical record.
Doses of oral antiplatelet drugs
Among the whole study population (5887), there were 2068 patients taking loading dose (150mg to 325mg) of aspirin, of which 1997 (96.6%) took a dose of 300mg. On the other hand, there were 3819 patients taking non-loading dose of aspirin (50mg to 100mg) and 3796 (99.4%) of these 3819 patients took the dose of 100mg.
Similarly, among the whole study population (5887), there were 2423 patients taking loading dose of P2Y12 inhibitors (746 and 1677 patients taking ticagrelor (180mg and 270mg) and clopidogrel (300mg to 600mg) respectively), of which 744 patients (99.7% of 746) took ticagrelor of 180mg and 1407 patients (84.0% of 1677) took clopidogrel of 300mg.
On the other hand, 3464 patients took non-loading dose of P2Y12 inhibitors (290 patients taking ticagrelor and 3174 taking clopidogrel). There were 283 patients (97.6% of 290) took ticagrelor of 90mg and 3004 patients (94.4% of 3174) took clopidogrel of 75mg.
Exclusion of patients as a result of lacking important clinical data
A total of 316 patients were excluded due to missing data of hemoglobin (214 patients), serum creatinine (136 patients), killip class (84 patients), heart rate (15 patients), blood pressure (14 patients), access site of PCI (85 patients), and past medical history (28 patients). Each of these patients may have more than one missing data but could be counted only once. These missing data were mainly due to the absence of records in patients' original medical records. STEMI, ST-elevation myocardial infarction.
*Non-loading dose of both clopidogrel and aspirin was reference standard. Figure S3 . Subgroup Analyses for Primary Safety Outcomes of the Whole Study Population. ACS, acute coronary syndrome; CI, confidence interval ; GP, glycoprotein; GRACE, Global Registry of Acute Coronary Events; HR, hazard ratio. Figure S4 . Subgroup Analyses for Primary Effectiveness Outcomes of the Propensity Score-Matched Population. ACS, acute coronary syndrome; CI, confidence interval ; GP, glycoprotein; GRACE, Global Registry of Acute Coronary Events; HR, hazard ratio. Figure S5 . Subgroup Analyses for Primary Safety Outcomes of the Propensity Score-Matched Population. ACS, acute coronary syndrome; CI, confidence interval ; GP, glycoprotein; GRACE, Global Registry of Acute Coronary Events; HR, hazard ratio. 
